Relapse Time Prolonged In Clinically Stable Patients With Bipolar I Disorder Treated With Quetiapine As Adjunct Therapy To Mood Stabilisers
AstraZeneca announced the online publication of long-term SEROQUEL® (quetiapine fumarate) clinical trial data in the Journal of Affective Disorders. Results show that SEROQUEL in combination with lithium or divalproex significantly increased the time to recurrence of any mood event in patients with bipolar I disorder compared with lithium or divalproex alone.
